In the CURE study, 12562 patients presenting with acute coro- nary syndromes without ST-segment elevation were random- ized to aspirin alone or aspirin plus clopidogrel for 3 to 12 months. The primary outcome (cardiovascular death, nonfatal MI, or stroke) occurred in 9.3% of patients treated with aspi- rin plus clopidogrel compared with 11.4% in patients treated with aspirin alone (P<0.001).32 In the subgroup of patients who ultimately underwent CABG after enrollment in the trial, there was a trend favoring aspirin plus clopidogrel with a reduction of the primary outcome (14.5% versus 16.2%, aspirin plus clopidogrel versus aspirin alone; RR, 0.89; 95% CI, 0.71 1.11). However, that benefit was entirely preopera- tive while the patients were awaiting surgery, and no benefit for clopidogrel was demonstrated for CURE patients after In response to a suggestion that dual antiplatelet therapy may be beneficial after CABG, Kim et al35 evaluated a large administrative database to compare the early clinical outcomes of 3268 patients who received both clopidogrel and aspirin early after CABG (with or without cardiopulmonary bypass) with those of 11799 patients who were treated with aspirin alone. Using propensity-score analysis, the authors found that compared with aspirin alone, dual antiplatelet therapy was associated with lower in-hospital mortality (1.0% ver- there was no difference in the rate of ischemic events (1.3% surprisingly, bleeding events were significantly lower in the group who received both aspirin and clopidogrel (4.2% versus cerns about selection bias. Similar findings were reported by S rensen et al,36 who evaluated the efficacy of clopidogrel after CABG using administrative data from 3545 patients in Denmark. Using multivariate analysis, the authors reported a lower risk of death (adjusted HR, 0.34; 95% CI, 0.20 0.61) in patients who received clopidogrel after surgery. 